Vitocalcit

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitocalcit

Property Description
Active Ingredient Alfacalcidol (1alpha-hydroxycholecalciferol)
Form Soft capsules (oral)
Pharmacological Class Vitamin D Analogue / Derivative (ATC: A11CC03)
General Purpose To support calcium and bone balance
Origin Synthetic prodrug

Identity and Classification: A Vitamin D Analogue

Vitocalcit is the commercial designation for the medicinal product containing the active substance Alfacalcidol, which is a synthetic analogue that falls within the pharmacological class of Vitamin D derivatives. This means the compound is chemically engineered to mimic the structure and function of the active vitamin hormone, Calcitriol (1,25-dihydroxyvitamin D3), in the body. Alfacalcidol is a derivative designed to modify the body's mineral homeostasis.


Composition and Form: Capsules and Active Conversion

The medicine is supplied primarily for oral administration as a single-ingredient formulation, often in the form of soft capsules containing the active ingredient suspended in an oily liquid vehicle. Alfacalcidol functions as a prodrug, requiring only one rapid conversion step in the liver to become the active hormone, Calcitriol. This analogue is utilized to enhance the intestinal absorption of calcium and phosphate. The specific synthesis of Alfacalcidol ensures that it bypasses the final activation step normally performed in the kidneys, making it a reliable therapeutic option.


General Purpose: Supporting Mineral and Bone Balance

The high-level purpose of Vitocalcit is to consistently normalize disturbances in calcium and phosphate metabolism. This reliable delivery of the active hormone is crucial for maintaining the body's calcium homeostasis and for stimulating the intestinal absorption of essential minerals from the diet. By effectively restoring proper mineral absorption, the medicine supports the essential process of mineralization, thereby aiding in the maintenance of the structural integrity of the skeletal system.

What side effects are possible with Vitocalcit?

Possible Side Effects and Safety Information

The safety profile of Vitocalcit (Alfacalcidol) is primarily characterized by effects related to its action on mineral homeostasis, which is consistent with its classification as a Vitamin D analogue.

Frequency-Classified Adverse Reactions

The most frequently documented undesirable effects are linked to disruptions in calcium and phosphate balance. The following adverse reactions are grouped according to frequency classifications used in regulatory documents:

  • Common (may affect up to 1 in 10 people): Hypercalcaemia (elevated calcium in the blood), Hyperphosphataemia (elevated phosphate in the blood), abdominal pain or discomfort, rash, and pruritus (itching).
  • Uncommon (may affect up to 1 in 100 people): Nausea, vomiting, diarrhoea, constipation, headache, confusional state, renal impairment, and Nephrolithiasis (kidney stones).
  • Rare (may affect up to 1 in 1,000 people): Dizziness.

System-Organ and Serious Consequences

Adverse effects are categorized across multiple System-Organ Classes, including Metabolism and Nutrition Disorders, Gastrointestinal Disorders, and Renal and Urinary Disorders. The potential for acute renal failure is documented as a serious, though Uncommon, adverse reaction, which can result from unmanaged, prolonged Hypercalcaemia.

Safety Considerations for Special Populations

Close safety monitoring is required for specific patient groups. For individuals with Renal Impairment, frequent and strict monitoring of serum calcium, phosphate, and creatinine is essential. The medicine is formally contraindicated (should not be used) in patients with pre-existing Hypercalcaemia.

Overdose and Emergency Response

Overdose and When to Seek Help

The documented clinical profile of a Vitocalcit (Alfacalcidol) overdose is centered on the development of Hypercalcaemia (elevated calcium in the blood), which represents the core toxicity. Progressive or severe hypercalcaemia may become so severe as to require emergency treatment.

Classification Official Regulatory Statement
Core Toxicity Hypercalcaemia (elevated plasma calcium).
Emergency Mandate Immediate cessation of Vitocalcit is required upon confirmed toxicity.

Documented Clinical Manifestations Initial signs of toxicity listed in regulatory documents include non-specific symptoms such as nausea, vomiting, headache, weakness, excessive thirst (polydipsia), and frequent urination (polyuria). Confusional states and somnolence may also be observed. Laboratory findings commonly include Hypercalciuria and Hyperphosphataemia.

Severe Outcomes and Required Action Uncorrected overdose may lead to severe systemic effects. Regulator-described serious outcomes include transient or long-lasting deterioration of kidney function, the formation of kidney stones (nephrolithiasis), and the risk of cardiac arrhythmias. Patients with underlying renal failure or on regular dialysis are explicitly noted as being particularly prone to hypercalcaemia. Management is officially described as symptomatic and supportive. The labeling requires close monitoring of plasma calcium, renal function, and ECGs (electrocardiographs) during the management of overdose.

Therapeutic Uses of Vitocalcit

What Vitocalcit treats: main uses and benefits

Vitocalcit is a specialized prescription medication generally used to help with severe and chronic problems related to the body's mineral and bone balance, relevant in conditions characterized by periods of heightened symptoms. It is considered relevant in contexts involving temporary physiological imbalance and applied across domains where additional symptomatic support is needed. It plays a role in managing several disorders of calcium metabolism and bone.

The medication is commonly used to help with skeletal diseases, including Renal Osteodystrophy, certain types of Osteomalacia (softening of the bones), and persistent Hypocalcemia (low calcium levels) due to conditions like Hypoparathyroidism or chronic kidney failure. These applications help address symptom clusters that may become intense or disruptive and interfere with daily functioning.

“Therapy is commonly used when the symptomatic burden is caused by the body’s compromised ability to maintain essential calcium levels due to underlying chronic disease.”

It assists with addressing symptoms related to systemic imbalance and may assist patients with managing symptoms related to physical discomfort, supporting general well-being during symptomatic phases.


Quick Fact: Support for Symptoms of Physical Discomfort The medicine is commonly used to help ease discomfort associated with impaired bone mineralization, relevant in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines Application

Eligibility and Restrictions for Use

Who Can and Cannot Use Vitocalcit?

The population eligibility for Vitocalcit (Alfacalcidol) is defined strictly by official government regulatory documents, focusing on absolute contraindications and necessary restrictions.

Eligibility Scope

Classification Status as per Regulatory Label
Populations for whom use is contraindicated Patients with Hypercalcaemia, Hyperphosphatemia, Metastatic Calcification, or Hypersensitivity to the active substance or excipients (e.g., arachis oil) [1.1, 1.2]. Concurrent use with digitalis glycosides is prohibited if hypercalcaemia is present [1.2].
Populations for whom use is allowed Adults with Chronic Renal Failure and those with various disorders of calcium metabolism, including Hypoparathyroidism and certain forms of Osteomalacia [1.4, 1.6]. Use is also documented for Neonates and Children in specific conditions [1.4].
Age-related eligibility rules Use in Neonates and Children is documented for specific indications; however, some regional prescribing information states that safety and efficacy in the Pediatric and Geriatric populations are not established [1.4, 1.2].
Pregnancy and lactation eligibility Use during pregnancy and lactation is not recommended or should be avoided unless clearly necessary, due to the documented risk of complications related to hypercalcaemia [1.2].
Eligibility-related restrictions Use requires frequent monitoring of serum calcium and phosphate, particularly in patients with Chronic Renal Failure or Granulomatous diseases (e.g., Sarcoidosis), where caution is advised due to altered Vitamin D sensitivity [1.2, 1.7].

What should I know about interactions with other medicines?

The official regulatory profile for Vitocalcit (Alfacalcidol) interactions is defined by its effects on mineral balance and its pharmacokinetic behavior, mandating specific constraints based on documented interaction patterns.

Interactions Affecting Mineral Homeostasis

Concurrent use of digitalis glycosides is formally contraindicated if the patient is experiencing hypercalcaemia, due to the increased potential for cardiac arrhythmias. The risk of hypercalcaemia is significantly heightened—an additive pharmacodynamic effect—by co-administration with other Vitamin D containing preparations, thiazide diuretics, and calcium-containing products. For this reason, concurrent use with other Vitamin D analogues is required to be avoided. A related population note exists for patients with granulomatous diseases, such as sarcoidosis, where sensitivity to Vitamin D is increased.

Metabolic and Absorption Constraints

Alfacalcidol's metabolic clearance is increased by certain anticonvulsants, including phenytoin and carbamazepine. These medicines have enzyme-inducing effects, representing a pharmacokinetic interaction that alters Alfacalcidol's processing. Separately, Alfacalcidol may increase the intestinal absorption of heavy metals. Consequently, the use of magnesium-containing antacids/laxatives must be avoided, and monitoring is required when using aluminium-containing preparations. Furthermore, to prevent absorption interference, Alfacalcidol must be administered at least 1 hour before, or 4 to 6 hours after the intake of bile acid sequestrants (like cholestyramine) or mineral oil.

Mechanism of Action

How Vitocalcit Works: Mechanism of Action

Vitocalcit (Alfacalcidol) is rapidly converted in the liver to Calcitriol (1,25-dihydroxyvitamin D), the active hormone. Calcitriol acts as a VDR (Vitamin D Receptor) agonist, binding to this nuclear transcription factor in target cells. This binding initiates a genomic cascade, regulating the transcription of proteins crucial for mineral transport, primarily in the intestine and kidney. VDR activation in the intestines enhances the synthesis of proteins that promote the absorption of calcium and phosphate from the diet, while activation in the kidneys promotes mineral reabsorption. Furthermore, Calcitriol binds to VDRs in the parathyroid glands to directly suppress the secretion of Parathyroid Hormone (PTH). The combined effect of increased circulating mineral availability and PTH suppression shifts the metabolic balance to favor mineral incorporation into the bone matrix, supporting the appropriate composition of the skeletal structure.

Dosage and Administration Information

Administration Scope

Vitocalcit administration follows specific protocols. The medication is used for oral use via soft gelatin capsules or liquid drops, and it is also indicated for intravenous injection in specific clinical settings, such as for patients undergoing dialysis. Oral formulations are typically administered once daily.

Dosing and Titration

Dosing involves an individualized regimen structured for titration rather than a fixed schedule. The common adult starting dose is 1.0 mcg daily, though older adults typically begin with a lower 0.5 mcg dose. The dose is adjusted, often by 0.25 - 0.5 mcg increments, based on plasma calcium levels, with adjustments occurring every two to four weeks. The dose is taken at the same time each day and may be ingested with or without food.

Special Procedural Conditions

A requirement for the efficacy of treatment is an adequate daily intake of calcium from external sources. Furthermore, if biochemical monitoring reveals excessive blood calcium (hypercalcemia), the standard procedure involves the immediate cessation of the medicine. The drug is subsequently restarted at half the last effective dose once calcium levels return to the normal range. Capsules are swallowed whole, and if a dose is missed, it is not doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vitocalcit (Alfacalcidol)


Evidence for Use in Chronic Kidney Disease (CKD) and Bone Disease

Studies primarily focused on patients with advanced Chronic Kidney Disease (CKD), including those on dialysis, to monitor biomarkers related to mineral and bone health. Trials examined changes in Parathyroid Hormone (PTH) levels and evaluated the consistency of calcium and phosphate in the blood. Studies monitored changes in PTH levels and described patterns related to the monitored levels of blood calcium and phosphate. Research explored associations with outcomes like cardiovascular events or all-cause mortality, with findings reported as mixed.

Long-term outcomes in CKD are not fully established. The analogue was studied for its association with long-term cardiovascular health outcomes, but the certainty remains low. Data show patterns related to the need for careful monitoring in these populations because of the observed risk of high blood calcium levels (hypercalcemia) in some participants.


Evidence for Use in Hypoparathyroidism (HypoPT) and Low Calcium

Research explored the analogue in studies related to calcium balance in Hypoparathyroidism (HypoPT). These studies monitored whether the analogue was used in trials that aimed to maintain stable calcium levels and examined the concurrent requirements for elemental calcium supplementation. Findings describe patterns observed where the analogue was studied for its influence on serum calcium concentrations. However, the studies also consistently monitored for the potential for hypercalcaemia (too much calcium in the blood) or hypercalciuria (too much calcium in the urine), which was observed in some participants.

Evidence for this indication is often derived from smaller cohorts, and comparative evidence is lacking against all other long-term calcium management strategies.


Evidence in Osteoporosis and Osteomalacia Research

Research examined the active ingredient in studies for conditions like Osteomalacia and Osteoporosis, particularly in postmenopausal women and older adults. Trials evaluated the incidence of bone breaks, specifically non-vertebral fractures, and changes in Bone Mineral Density (BMD). Studies examined how outcomes related to non-vertebral fractures and changes in muscle function evolved in the observed populations.

Findings related to the analogue as a single agent in studies focused on vertebral fractures and BMD changes were described as mixed. Evidence quality varies, and some meta-analyses combine data with other related vitamin D analogues, which contributes to the broader evidence landscape. Subgroup findings are uncertain, and results apply only to the specific populations studied.


What is Still Uncertain About the Research

A key limitation across the research is that many studies did not include the incidence of major long-term clinical events, such as all-cause mortality or severe cardiovascular problems, especially in CKD patients. Findings were mixed or inconclusive in these areas, and the certainty remains low. Additionally, comparative evidence is lacking in some areas against established therapies. Research provides context but not individual predictions.

Key Studies & References

  1. Application for addition of new medicines: Alfacalcidol and Calcitriol (Vitamin D Analogues and Calcium Supplementation) - Essential Medicines Application
  2. National Institute for Health and Care Excellence (NICE) Clinical Guideline [CG185] - Hyperparathyroidism (primary): diagnosis, assessment and initial management

Frequently Asked Questions (FAQ)

Common questions about Vitocalcit (FAQ)


Q: What is the main reason doctors prescribe Vitocalcit?

A: According to official regulatory documents, Vitocalcit is prescribed for conditions involving a disturbance of calcium metabolism. These main uses include the management of conditions such as renal osteodystrophy (bone disease related to kidney failure) and certain forms of hypoparathyroidism.

Q: How quickly can I expect to notice anything after starting Vitocalcit?

A: Studies and official information indicate that the active form of the medicine begins working relatively quickly compared to native Vitamin D. While patient experience varies, effects on blood markers, such as Parathyroid Hormone (PTH) levels, are typically observed over the first few weeks of treatment.

Q: Is Vitocalcit the same as over-the-counter calcium supplements?

A: No, Vitocalcit is not the same as standard over-the-counter supplements. It is classified as a prescription-only Vitamin D analogue medicine. This means it is a synthetic substance that is prescribed by a healthcare professional.

Q: Are there any food or drinks that should be avoided when taking Vitocalcit?

A: Official drug documents state that interactions with food have not been established for this medicine. However, because the medicine increases mineral absorption, it is important that total dietary intake of calcium and phosphorus is carefully monitored to avoid high blood levels.

Q: Is Vitocalcit safe for use during pregnancy?

A: Official regulatory warnings advise against the use of this medicine during pregnancy unless clearly necessary. This is because high calcium levels (hypercalcaemia) while pregnant may pose a risk to the developing offspring, and overall safety has not been fully established.

Q: Can people with kidney stones use Vitocalcit?

A: Official product information advises that caution is needed when prescribing this medicine to patients who have a history of renal stones (kidney stones). The development of new kidney stones is also listed as a possible adverse reaction to the medication.

Q: Why does the packaging for Vitocalcit mention 'limited sunlight exposure'?

A: The direction to limit sunlight exposure applies to the medicine itself. Official product information advises that the capsules and drops should be protected from direct sunlight and stored properly. This is necessary to ensure the medicine remains chemically stable and fully effective.

Q: What is the difference between Vitocalcit and similar drugs that treat bone density?

A: Vitocalcit is a Vitamin D analogue, meaning it is a synthetic version of the active Vitamin D hormone. Clinical data show differences in effects on bone mineral density and fracture rates when compared to native Vitamin D.

Q: Are there any official warnings about driving or operating machinery while on Vitocalcit?

A: Official patient information advises that if a patient experiences side effects affecting the central nervous system, such as a confusional state or dizziness, operating machinery and driving is generally not recommended.

Q: What is the typical duration of treatment with Vitocalcit?

A: Studies and regulatory documents indicate that this medicine is typically intended for long-term use to manage chronic conditions, such as those related to kidney disease, and maintain stable mineral and hormone levels.

Q: Can children or teenagers use Vitocalcit?

A: Official documents indicate that the main indications are for adult patients. The safety and efficacy of this medicine have not been established in children (pediatric populations), and its use requires specialist guidance.

Q: Are there generic versions of Vitocalcit available?

A: Yes. The active substance in Vitocalcit is Alfacalcidol, which is the internationally recognized generic name for the medicine. Different brands, and often generic versions, containing Alfacalcidol are available depending on the region.

Q: Does Vitocalcit contain lactose or gluten?

A: The active ingredient, Alfacalcidol, does not contain lactose or gluten. The inactive ingredients used in the capsule formulation typically include substances such as sesame oil, gelatin, and glycerol.

Q: Can men use Vitocalcit, or is it primarily for women?

A: The medicine is indicated for use in adult patients with chronic conditions like renal failure and hypoparathyroidism. Official clinical data and indications confirm that it is prescribed to both men and women.

Q: Are there any age restrictions mentioned in the official drug information for Vitocalcit?

A: Yes. The main indications for the medicine are for adult patients. Official documents state that the safety and efficacy have not been established in children, meaning pediatric use is generally restricted.

Q: Does alcohol consumption interfere with Vitocalcit?

A: Official drug documents do not list a direct interaction between alcohol consumption and Alfacalcidol. It is important that patients discuss alcohol intake with their healthcare provider, as this relates to individual risk and medical history.

Q: Why is a sudden change in how I feel a reason to call a doctor while taking Vitocalcit?

A: A sudden change in how a patient feels may be a sign of Hypercalcaemia (high blood calcium), the primary safety concern. Symptoms like nausea, vomiting, excessive thirst, and confusion indicate that blood mineral levels need urgent monitoring.

Q: Is Vitocalcit known to interact with herbal remedies?

A: Official drug documents state that interactions with herbal products have not been established. Patients are advised to inform their healthcare provider about any herbal remedies or non-prescription supplements they are currently using.

Q: Can a pharmacist answer questions about Vitocalcit?

A: Yes. Regulatory documents and patient information leaflets confirm that pharmacists, along with doctors, are available to address questions about the medication.

Q: Is Vitocalcit intended as a cure, or is it a long-term management treatment?

A: Official information confirms that the medicine is intended for the long-term management of chronic conditions, such as those related to kidney disease or hypoparathyroidism, rather than functioning as a cure.

Q: Is Vitocalcit considered a vitamin, supplement, or a prescription medicine?

A: Vitocalcit is classified as a prescription-only Vitamin D analogue medicine. It requires a prescription and is different from standard over-the-counter calcium or native Vitamin D supplements.

Q: Can Vitocalcit be taken long-term?

A: The treatment is typically intended for long-term use to manage chronic conditions and maintain stable levels of Parathyroid Hormone (PTH) and minerals.

Q: Can I take Vitocalcit with my high blood pressure medicine?

A: Concurrent use of certain medications, such as thiazide diuretics (a type of blood pressure medicine), is explicitly warned against because it may enhance the risk of hypercalcaemia. For this reason, patients are advised to inform their healthcare provider about all blood pressure medicines they are currently taking.

Q: Is there a different form of Vitocalcit available, like a liquid or chewable?

A: The medicine is generally available in various forms, including soft capsules and oral drops. In specific clinical settings, such as hospital treatment, it is also authorized for intravenous injection.

Q: How does Vitocalcit affect blood test results?

A: As the medicine works to regulate mineral levels, regular blood monitoring is typically required for treatment. Blood tests are used to check Parathyroid Hormone (PTH) levels and the concentrations of key minerals like calcium, phosphate, and creatinine.

Q: What are the signs of a serious, but rare, side effect from Vitocalcit?

A: The most serious concern is unmanaged, prolonged high blood calcium (hypercalcaemia). This can cause symptoms like nausea, vomiting, excessive thirst, and confusion, which may potentially lead to a serious but uncommon condition called acute renal failure.

Q: Do I need a special diet while using Vitocalcit?

A: The treatment requires an adequate daily intake of calcium from external sources for efficacy. While an official drug-food interaction is not established, the required monitoring of total calcium and phosphorus intake must be followed, as directed by a healthcare professional.

Q: Can I take Vitocalcit if I have a history of heart problems?

A: Caution is advised for patients with a history of cardiovascular diseases. Furthermore, the use of digitalis glycosides (a type of heart medicine) is formally contraindicated if the patient is simultaneously experiencing high blood calcium (hypercalcaemia).

Q: Does Vitocalcit make you feel tired or dizzy?

A: Official information lists dizziness as a rare adverse reaction. Additionally, signs of high blood calcium (hypercalcaemia) can include confusional state and general fatigue.

Q: Does Vitocalcit require a prescription, or is it available over the counter?

A: Vitocalcit is a medicine that requires a prescription. This is because the dosing is highly individualized and requires close, professional monitoring of blood mineral levels by a physician.

Q: Why do some sources say Vitocalcit should be taken with food?

A: Official instructions state the medicine can be taken with or without food. Taking it with food may be recommended by some healthcare sources because it can help reduce potential gastrointestinal side effects like nausea or stomach upset.

Q: Can I take other supplements, like magnesium, while on Vitocalcit?

A: Official warnings state that magnesium-containing antacids/laxatives are required to be avoided as they can increase the risk of too much magnesium in the blood. All supplements, particularly those containing calcium or Vitamin D, are advised to be discussed with a healthcare provider.

Q: What is the most important piece of safety information about Vitocalcit?

A: The most critical safety information is the potential for Hypercalcaemia (high blood calcium). This potential risk means that regular blood monitoring is typically required for patients taking the medicine, and may necessitate immediate cessation if levels are too high.

Q: What is the active ingredient in Vitocalcit?

A: The active ingredient contained in the capsule or drop formulation is Alfacalcidol. This substance is then rapidly converted in the liver to Calcitriol, which is the active hormone that produces the therapeutic effect.

Q: What are the restrictions on using Vitocalcit for people with pre-existing medical conditions?

A: The medicine is formally contraindicated (must not be used) in patients with pre-existing high blood calcium (hypercalcaemia). Caution is also advised when a patient has a history of kidney stones or certain cardiovascular conditions.

Q: What does 'contraindication' mean in the context of Vitocalcit?

A: A contraindication is a specific situation or pre-existing medical condition, such as high blood calcium, that makes the use of the medicine potentially harmful. When a drug is contraindicated, regulatory advice is that the drug is required to be avoided.

How should Vitocalcit be stored and disposed of?

The storage and disposal of Vitocalcit (Alfacalcidol) soft capsules must strictly adhere to regulatory labeling to maintain stability and ensure safety.

Official Storage Requirements

The medicine is required to be stored at room temperature, typically below 25 C or 30 C. To prevent degradation, the capsules must be protected from light and moisture. Always keep Vitocalcit in its original outer carton or container until the expiration date. It is mandatory to store this medicine out of the sight and reach of children due to the potential for harm from accidental ingestion.

Disposal Instructions

Discard unused or expired Vitocalcit safely. Do not throw the medicine away in household waste or wastewater. Follow official guidance by returning expired capsules to a pharmacist or participating in local drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitocalcit found in:

A-Z Index: